Physician profile
Daniel Aziz
NPI 1679159164
$1,826.11
in general payments reported to CMS, 2019-2025
16 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $695 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.21 |
| Education | $237.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $370.46 | 2024-2025 | Impella |
| Abbott Laboratories | $316.90 | 2024-2025 | Ensite, Dragonfly Opstar, Cardiomems |
| Kestra Medical Technology Services, INC. | $225.85 | 2025 | Assure Wcd |
| Amgen INC. | $198.81 | 2024-2025 | Repatha, Repatha |
| Pfizer INC. | $175.89 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $137.32 | 2024 | Inpefa |
| Atricure, INC. | $80.26 | 2024-2025 | Atriclip Laa Exclusion System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.48 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.01 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $39.94 | 2025 | |
| Novartis Pharmaceuticals Corporation | $36.74 | 2025 | |
| Merck Sharp & Dohme LLC | $33.87 | 2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $33.34 | 2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $31.37 | 2024-2025 | Camzyos |
| Stryker Corporation | $26.58 | 2025 | Flowtriever |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.29 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.